Detalles de la búsqueda
1.
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World.
Oncologist
; 2024 Mar 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-38520745
2.
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Br J Cancer
; 127(3): 383-393, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35264788
3.
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Br J Cancer
; 127(11): 2034-2042, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36175621
4.
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome.
Oncologist
; 27(2): e199-e202, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641202
5.
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.
Oncologist
; 27(2): 87-e115, 2022 03 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35641222
6.
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab.
Oncologist
; 27(6): e484-e493, 2022 06 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35429394
7.
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
Br J Cancer
; 123(1): 81-91, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32376889
8.
Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.
Oncologist
; 25(12): e1996-e2005, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32557976
9.
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Oncologist
; 24(8): 1128-1136, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31015312
10.
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
Int J Mol Sci
; 20(8)2019 Apr 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-30995715
11.
Detection of Loss of Heterozygosity in cfDNA of Advanced EGFR- or KRAS-Mutated Non-Small-Cell Lung Cancer Patients.
Int J Mol Sci
; 21(1)2019 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31861832
12.
Real-world impact of the introduction of chemo-immunotherapy in extended small cell lung cancer: a multicentric analysis.
Front Immunol
; 15: 1353889, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38322260
13.
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study.
Eur J Cancer
; 167: 81-91, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35398759
14.
Comprehensive analysis of T cell receptor repertoire in patients with KRAS mutant non-small cell lung cancer.
Transl Lung Cancer Res
; 11(9): 1936-1950, 2022 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-36248331
15.
Treatment strategies for locally advanced non-small cell lung cancer in elderly patients: Translating scientific evidence into clinical practice.
Crit Rev Oncol Hematol
; 163: 103378, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34087343
16.
Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in EGFR-Mutated Non-small Cell Lung Cancer: A Case Report.
Front Med (Lausanne)
; 8: 570921, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34179028
17.
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.
Transl Lung Cancer Res
; 10(1): 202-220, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33569305
18.
Real world data in the era of Immune Checkpoint Inhibitors (ICIs): Increasing evidence and future applications in lung cancer.
Cancer Treat Rev
; 87: 102031, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32446182
19.
Editorial: Updates on combination therapy for lung cancer volume II.
Front Oncol
; 14: 1393278, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38706598
20.
Neutrophil-lymphocyte ratio is prognostic in early stage resected small-cell lung cancer.
PeerJ
; 7: e7232, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31392087